These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9754466)

  • 21. Plasma oxalate in patients with chronic renal failure receiving continuous ambulatory peritoneal dialysis or hemodialysis.
    McConnell KN; Rolton HA; Modi KS; Macdougall AI
    Am J Kidney Dis; 1991 Oct; 18(4):441-5. PubMed ID: 1928062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin B6 requirements in chronic renal failure.
    Mydlík M; Derzsiová K; Guman M; Hrehorovský M
    Int Urol Nephrol; 1992; 24(4):453-7. PubMed ID: 1459821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of elevated plasma oxalic acid by pyridoxine therapy in patients on RDT.
    Balcke P; Schmidt P; Zazgornik J; Kopsa H
    Proc Eur Dial Transplant Assoc; 1983; 19():308-12. PubMed ID: 6878246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peritoneal urea and creatinine clearances in continuous peritoneal dialysis patients with different types of peritoneal solute transport.
    Tzamaloukas AH; Murata GH; Piraino B; Rao P; Bernardini J; Malhotra D; Oreopoulos DG
    Kidney Int; 1998 May; 53(5):1405-11. PubMed ID: 9573559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pyridoxine supplementation on plasma oxalate concentrations in patients receiving dialysis.
    Tomson CR; Channon SM; Parkinson IS; Sheldon WS; Ward MK; Laker MK
    Eur J Clin Invest; 1989 Apr; 19(2):201-5. PubMed ID: 2499479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of ascorbic acid and pyridoxine supplementation on oxalate metabolism in peritoneal dialysis patients.
    Shah GM; Ross EA; Sabo A; Pichon M; Reynolds RD; Bhagavan H
    Am J Kidney Dis; 1992 Jul; 20(1):42-9. PubMed ID: 1621677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis.
    Medcalf JF; Harris KP; Walls J
    Kidney Int; 2001 Mar; 59(3):1128-33. PubMed ID: 11231370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuous ambulatory peritoneal dialysis with a high flux membrane. A preliminary report.
    Nolph KD; Moore HL; Prowant B; Twardowski ZJ; Khanna R; Gamboa S; Keshaviah P
    ASAIO J; 1993; 39(3):M566-8. PubMed ID: 8268600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Independent effects of residual renal function and dialysis adequacy on dietary micronutrient intakes in patients receiving continuous ambulatory peritoneal dialysis.
    Wang AY; Sea MM; Ip R; Law MC; Chow KM; Lui SF; Li PK; Woo J
    Am J Clin Nutr; 2002 Sep; 76(3):569-76. PubMed ID: 12198001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of nitrogen balance in patients treated with continuous ambulatory peritoneal dialysis].
    Janaszak S; Grzegorzewska AE; Mariak I
    Pol Arch Med Wewn; 1998 Dec; 100(6):499-514. PubMed ID: 10405563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis.
    Delmez JA; Slatopolsky E; Martin KJ; Gearing BN; Harter HR
    Kidney Int; 1982 Jun; 21(6):862-7. PubMed ID: 6897087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperoxaluria and hyperoxalemia: one more concern for the nephrologist.
    Mitwalli A; Oreopoulos DG
    Int J Artif Organs; 1985 Mar; 8(2):71-4. PubMed ID: 3886558
    [No Abstract]   [Full Text] [Related]  

  • 33. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urea kinetic analysis of automated peritoneal dialysis allows calculation of a CAPD-equivalent Kt/V(urea).
    Schurman SJ; Shoemaker LR; Warady BA
    Kidney Int; 2000 Sep; 58(3):1318-24. PubMed ID: 10972696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Secondary oxalosis in chronic renal insufficiency].
    Balcke P; Schmidt P; Zazgornik J; Kopsa H; Deutsch E
    Z Urol Nephrol; 1982 Jun; 75(6):409-14. PubMed ID: 7124142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peritoneal dialysis adequacy and risk of death.
    Rocco M; Soucie JM; Pastan S; McClellan WM
    Kidney Int; 2000 Jul; 58(1):446-57. PubMed ID: 10886593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Water soluble vitamins in patients with chronic renal failure and effect of B6 administration of immunological activity.
    Kamata K; Okubo M; Marumo F
    Proc Clin Dial Transplant Forum; 1979; 9():194-6. PubMed ID: 552042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma free amino acids and their metabolites in Taiwanese patients on hemodialysis and continuous ambulatory peritoneal dialysis.
    Chuang CK; Lin SP; Chen HH; Chen YC; Wang TJ; Shieh WH; Wu CJ
    Clin Chim Acta; 2006 Feb; 364(1-2):209-16. PubMed ID: 16087168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher KT/V urea associated with greater protein catabolic rate and dietary protein intake in children treated with CCPD compared to CAPD. Mid-European Pediatric CPD Study Group (MPCS).
    Schaefer F; Wolf S; Klaus G; Langenbeck D; Mehls O
    Adv Perit Dial; 1994; 10():310-4. PubMed ID: 7999855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urea kinetic modelling in two groups of patients on continuous ambulatory peritoneal dialysis.
    Barton EN; Morgan AG; Burden RP
    West Indian Med J; 1997 Jun; 46(2):57-9. PubMed ID: 9260536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.